want to know more?
+31 (0)20 303 1970

drug discovery in the ubiquitin field

Access to well defined ubiquitinated peptides and conjugates, which could so far not be routinely produced (bio)chemically, is of paramount importance for screening assays for the identification of new drugs, as well as for fundamental research and structural studies. Find out about how our reagents enables research in the three stages of early drug discovery. 

target

Identify and validate your target using UbiQ Probes.

product info

lead

Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.  

product info

lead on target

Our reagents enable you in lead on target validation and lead optimization.

product info

reagents

about our products

UbiQ develops and commercializes ubiquitinated peptides, ubiquitin-based reagents and high throughput assays, which enable and expedite drug discovery in the rapidly expanding ubiquitin field. UbiQ, founded in 2010, is a spin-out of the Netherlands Cancer Institute (NKI), Amsterdam. 

view reagents    more info

custom made reagents

With our UbiQ technologies we are able to fully synthesize site-selective ubiquitinated peptides of native conformation, using automated solid phase peptide synthesis. This enables us to synthesize any custom made peptides.

news

  • UbiQ-news: Bio-orthogonally tagged activity-based probes for proteomics of deubiquitinating enzymes

    28 January 2019

    A recent paper in Nature Communications describes a collaborative effort between scientists at UbiQ, Genentech, Boston Biochem (Bio-Techne) and Stanford University (1). Here a reactive-site-centric chemoproteomics protocol is presented which allows evaluating activity and probe reactivity of deubiquitinating enzymes (DUBs, also termed deubiquitylases)......(more)

     

  • UbiQ-news: launch of an activity-based probe for the deubiquitinating enzyme OTULIN

    23 October 2017

    Hereby we present UbiQ-121 as an activity-based probe for OTULIN, a deubiquitinating enzyme that is specific for Met1 linked ubiquitin chains and acts as a negative regulator of nuclear factor κB signaling and immune homeostasis. UbiQ-121 is based on Met1 linked diubiquitin in which G76 of the distal ubiquitin is replaced by an electrophilic dehydroalanine (Dha) residue. The catalytic cysteine residue of OTULIN reacts in a covalent manner with the Dha residue and as such UbiQ-121 captures OTULIN in its active conformation .....(more)

     

  • UbiQ-news: UbiQ secures 2.7 mioEUR EUROSTARS grant to tackle SUMOylation

    12 September 2017

    UbiQ secures 2.7 mioEUR EUROSTARS grant to tackle SUMOylation.

     

     

     

  • UbiQ-news: launch of new reagents

    24 July 2017

    Ub photoLeu73 (UbiQ-154), a new and powerful crosslinkable Ub. UbiQ-154 is a new crosslinking reagent based on ubiquitin in which Leu73 is replaced by the photoreactive analog photoleucine.....(more)

     

© 2016 UbiQ Bio